


# ANGLO NORDIC

2004 - 2024



The Anglonordic Life Science Conference  
COUNTY HALL, LONDON, 18 APRIL 2024

**CONFERENCE BROCHURE**

Tap for  
more

# Contents

Tap an item to view

[Introduction](#)



[Our Sponsors](#)



[Programme](#)



[Speakers](#)



[Technology Room Pitches: Morning](#)



[Biotech Room 1 Pitches: Morning](#)



[Biotech Room 2 Pitches: Morning](#)



[Technology Room Pitches: Afternoon](#)



[Biotech Room 1 Pitches: Afternoon](#)



[Biotech Room 2 Pitches: Afternoon](#)



[Exhibitors](#)



[Delegations](#)



[Charity of the Year](#)



[Attending Investors](#)



[Attending Companies and Organisations](#)



The logo for IMI Ventures features the letters 'IMI' in a large, bold, teal font. Below it, the word 'ventures' is written in a smaller, teal, lowercase sans-serif font. The background is a vibrant purple and pink gradient with abstract, overlapping geometric shapes.

# IMI ventures

A leading global  
strategic corporate VC  
investing in visionary  
Biotechnology and  
Technology companies

## **INTERNATIONAL STRATEGIC COMMUNICATIONS FOR LIFE SCIENCES, HEALTHCARE & INDUSTRIAL BIOTECHNOLOGY**

We are specialists, with an indepth understanding of how to communicate complex life science stories to financial and pharma audiences. We have been trusted by hundreds of clients, both public and private, large and small, to help them on their journey.

- ✓ Corporate communications
- ✓ Narrative development
- ✓ Media relations
- ✓ Profile raising
- ✓ Digital and social media
- ✓ Presentation development
- ✓ Conference support
- ✓ Content development
- ✓ Investor relations
- ✓ Financing support
- ✓ Private financing
- ✓ IPOs
- ✓ M&A
- ✓ Investor perception studies
- ✓ Presentation training

**Optimum Perspectives Podcast:**  
Bringing together key industry thought leaders



# Dear Delegate,

We are delighted to welcome you to the 20<sup>th</sup> anniversary of the annual Anglonordic Life Science Conference in London!

When I started the conference 20 years ago, there was almost no communication between the European countries within the life science industry, both in terms of funding and partnerships. This was one of the big reasons why I created the conference.

Things are different today, with almost all actors working globally. Over the years, the Anglonordic Conference has grown alongside these international developments, and today we are proud to welcome a record number of investors and companies from across Europe and beyond.

On behalf of the Organising Committee and Conference Team, I hope you all benefit from the insights, networking and partnerships on offer today.

Your sincerely

Mr Mattias Johansson

*Founder, Anglonordic Life Science  
Conference*



# Our Sponsors

FOUNDING SPONSOR



SILVER SPONSOR



RECEPTION SPONSOR



PARTNERING SPONSOR



LUNCH SPONSOR



AFTERNOON DRINKS SPONSOR



SUPPORTING SPONSORS



MEDIA PARTNERS



# Programme

All programme items will take place in Biotech Room 1 unless otherwise stated

**08:00 – 08:45 Registration**

**08:45 – 08:50 Welcome**

*Mary Clark, CEO, Optimum Strategic Communications*

*Hakan Goker, Managing Director, M Ventures*

*Mattias Johansson, CEO, Ezenze Limited*

**08:50 – 09:15 The Future Landscape of Business Development**

*Shaun Grady, SVP, Business Development Operations,*

**AstraZeneca**

**09:15 – 10:00 Panel: Neurodegeneration - Novel approaches and targets**

Chair:

*Lisa Urquhart, Biopharma Editor & Writer*

Panelists:

*Anker Lundemose, CEO, Mission Therapeutics*

*Paul Little, CEO, Vesper Bio*

*Barbara Angehrn Pavik, CEO, Asceneuron*

*Jane Osbourn, CSO, Alchemab Therapeutics*

# Programme

**10:00 – 10:30 Coffee Break**

**10:30 – 11:45 Pitch Presentations**

<b>Bioconvergence</b>	<b>Clinical Stage</b>	<b>Dx and More</b>
<i>Technology Room</i>	<i>Biotech Room 1</i>	<i>Biotech Room 2</i>
Moderated by Stephen Adams, Optimum Strategic Communications	Moderated by Noga Yerushalmi, M Ventures	Moderated by Bauke Anninga, M Ventures
ANYO Labs	4C Biomed	Protein Alternatives
Kvantify	Kiox Pharma	ADOR Diagnostics
Iktos	Minovia Therapeutics	DoMore Dx
Celtarys Research	Kling Bio	AlgoDx
Liva Healthcare	Bsense	Scandion Oncology
Quant Health	LifT Biosciences	

**11:45 – 12:45 Investors' Panel - Trends in Life Science Investments**

Chair:

**Stephen Hansen**, *Director of Biopharma Intelligence, BioCentury*

Panelists:

**Hakan Goker**, *Managing Director, M Ventures*

**Allan Marchington**, *Head of Life Sciences, ICG*

**Roel Bulthuis**, *Managing Partner, Syncona*

**Erica Whittaker**, *VP, Head of Corporate Venture Fund, UCB*

# Programme

## 12:45 – 13:45 Networking Lunch

Sponsored by **COMAC MEDICAL**

## 13:45 – 14:30 Panel: What Next for Cell and Gene Therapies

Chair:

**Megan Thomas**, *Multimedia Editor, Drug Discovery World*

Panelists:

**Jérémie Laurent**, *CEO, Astraveus*

**Christian Uhrich**, *Investment Director, M Ventures*

**Miquel Vila-Perelló**, *CEO, SpliceBio*

**Arnaud Autret**, *Head of European Operations, Illumina Ventures*

## 14:30 – 15:45 Pitch Presentations

<b>Novel Tech Solutions for the Life Sciences</b>	<b>More in Drug Development</b>	<b>New modalities and administration methods</b>
<i>Technology Room</i> Moderated by Oliver Hardick, M Ventures	<i>Biotech Room 1</i> Moderated by Eva Haas, Optimum Strategic Communications	<i>Biotech Room 2</i> Moderated by Nadiya Ishnazarova, M Ventures
Tissue Dynamics Clair Scientific Genopore Denovai Cerebriu Semarion	Outrun Tx Rewind Pluvia Biotech Carocell Bio Brigid Biologics Ambrose Healthcare	Creasallis Alder Tx Mikrobiomik Engimmune LightOx Limited Metalead Therapeutics

# Programme

**15:45 – 16:15 Coffee Break**

**16:15 – 17:15 If I Knew Then What I Know Now**

Chair:

**Mike Ward**, *Global Head of Life Sciences & Healthcare  
Thought Leadership, Clarivate*

Panelists:

**Khatereh Ahmadi**, *Head of Search and Evaluation BD&L,  
Europe, MSD*

**Christoph Vahl**, *Executive Director, Head of External Innovation  
Oncology, Merck*

**Tim Edwards**, *Chairman, STORM Therapeutics*

**Simon Kerry**, *CEO, Curve Therapeutics*

**17:15 – 17:25 Roald Dahl's Marvellous Children's Charity**

**Mike Allen**, *Business Development Manager*

**Shyam Matharu**, *Corporate Partnerships Manager*


**17:25 – 17:30 Conclusions**

**17:30 – 18:30 Afternoon Drinks Reception**

Hosted by



Contents



# Speakers

Tap the LinkedIn icon on each Speaker to view their biography.



**Khaterah Ahmadi**

*Head of Search and Evaluation  
BD&L, Europe*

**MSD**



**Barbara Angehrn Pavik**

*CEO*

**Asceneuron**



**Arnaud Autret**

*Head of European Operations*

**Illumina Ventures**



**Roel Bulthuis**

*Managing Partner*

**Syncona**

# Speakers



**Mary Clark**

*CEO*

**Optimum Strategic  
Communications**



**Tim Edwards**

*Chairman*

**STORM Therapeutics**



**Hakan Goker**

*Managing Director*

**M Ventures**



**Shaun Grady**

Vice President, Strategic Partnering  
& Business Development

**AstraZeneca**

# Speakers



**Stephen Hansen**

*Director of Biopharma Intelligence*

**BioCentury**



**Mattias Johansson**

*CEO*

**Ezenze**



**Simon Kerry**

*CEO*

**Curve Therapeutics**



**Jérémie Laurent**

*CEO*

**Astraveus**

# Speakers



**Paul Little**

*CEO*

**Vesper Bio**



**Anker Lundemose**

*CEO*

**Mission Therapeutics**



**Allan Marchington**

*Head of Life Sciences*

**ICG**



**Jane Osbourn**

*CSO*

**Alchemab Therapeutics**

# Speakers



**Megan Thomas**

*Multimedia Editor*

**Drug Discovery World**



**Christian Urich**

*Investment Director*

**M Ventures**



**Lisa Urquhart**

*Biopharma Editor and  
Writer*



**Christoph Vahl**

*Executive Director, Head of  
External Innovation Oncology*

**Merck**

# Speakers



**Miquel Vila-Perelló**

*CEO*

**SpliceBio**



**Mike Ward**

*Global Head of Life Sciences &  
Healthcare Thought Leadership*

**Clarivate**



**Erica Whittaker**

*VP, Head of Corporate Venture*

**UCB Ventures**

Contents






# Tech Room Pitches: Morning

**Theme: Bioconvergence**

**Moderator:** Stephen Adams, Optimum Strategic Communications



ANYO LABS

**Presenter:** Albin Boman, CEO

ANYO Labs was founded in 2022 as a collaboration between researchers in physical and computational chemistry Leif A. Eriksson and Sayyed Jalil Mahdizadeh, and a management team with broad competencies from the entrepreneurial ecosystem of Gothenburg. The technology is based on artificial intelligence tools that bring new levels of efficiency to virtual library screening and denovo drug discovery. Lead optimisation, scaffold decoration as well as protein-protein interaction tools based on the unique approach allowed for a tailored approach to find hits and generate lead compounds in record times. This allows for true de novo unknown chemical space expansion unlike ever before.



**Presenter:** Nils Anton Berglund,  
Head of Strategic Alliances

Kvantify is a software company working within drug discovery. We believe that the best solution in the future includes both quantum and classical computing. Classical brings speed, quantum brings precision. We are a strong, cross-functional team of 40+ PhDs with expertise in both areas. This helps us provide value both today and tomorrow. Our main focus area is drug discovery where we develop software to speed up the pre-clinical phase and increase success rates. We recently launched a product for unbinding kinetics, called koffee, as the calculations take the same time as brewing a cup of coffee.



**Presenter:** Yann Gaston-Mathé,  
CEO and Co-Founder

Iktos is a next generation AI and  
Robotic-driven drug discovery

company. Founded in 2016, we have developed a unique generative AI technology with synthetic feasibility at its core and combined it with robots to considerably accelerate drug discovery. We have partnered with leading pharmaceutical companies, biotechs, and academic institutions worldwide over the past years to bring innovative treatments to market faster and more efficiently either via collaboration or sales of our AI-sofwares. In addition, we are advancing an internal pipeline in oncology and immuno-inflammation and are open to partnerships on programs in our internal pipeline.



**Celtarys**  
RESEARCH

**Presenter:** Alessandro Scandurra,  
Head of Strategy in Business Model  
Innovation

Celtarys is a biotech company dedicated to supporting the design and development of the best possible drugs in the fastest and most effective manner. Celtarys has pioneered a functional precision chemistry platform rooted in advanced linkerology. This platform effectively guides the creation of intricate chemical structures applicable to areas such as PROTAC, Therapeutic Antibodies, and Biosensors. These innovative compounds, unattainable through conventional chemistry, streamline and accelerate the screening process for novel therapeutic candidates. As a result, they significantly reduce the need for validations and consequently lower the high costs associated with the early phases of drug discovery.



**liva**

**Liva Healthcare**

**Presenter:** Shahram Sharif, CEO

Liva is a leading digital therapeutics company that advances digital-first delivery of behaviour change programmes to improve health outcomes globally, at scale. Our team of dedicated healthcare professionals create personalised change programmes to support people in their journey to prevent, manage and treat obesity, type-2 diabetes and prediabetes and other cardiometabolic conditions. The safety and efficacy of our digital therapeutic programmes are well-supported by extensive evidence from randomised controlled

trials (RCTs) and other clinical studies. Liva's innovative digital-first coaching platform integrates seamlessly into healthcare systems offering personalised clinical support to more than 50,000 patients.



**QUANTHEALTH**

**Presenter:** Orr Inbar,  
Founder and CEO

90% of drugs fail the clinical stage, representing a direct \$50B annual waste to pharma companies. To address this challenge at its core, QuantHealth's Clinical-Simulator predicts how any patient in a clinical trial will respond to treatment, allowing trial design teams to virtually execute thousands of variations for the trial protocol to optimize trial design. Based on its novel AI engine and a vast dataset of 350m patients and over 700K drug data entities, QuantHealth's simulator can predict clinical trial results with 86% accuracy, allowing users to answer mission critical questions such as cohort optimization, indication selection, in-licensing asset evaluation, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe and Israel, and is supported by an advisory board of physicians and scientists from leading academic institutions and pharma companies.



# Biotech Room 1 Pitches: Morning

**Theme: Clinical Stage**

**Moderator:** Noga Yerushalmi, M Ventures



**Presenter:** Eyal Greenberg

4C Biomed is a pre-clinical stage  
Immuno-Oncology therapeutic

company with operations in the UK and a subsidiary in Israel.

Our primary mission at 4C Biomed is to identify targets that allow us to develop innovative and potent drugs, such as monoclonal antibodies, designed to leverage a patient's immune system in the fight against cancer. Our superior and systematic discovery platform has proven exceptionally efficient at highlighting targets for drug development, enabling us to create an experimentally derived data bank of potential targets.

We have recently filed a patent (national phase) for our proprietary lead,  $\alpha$ 4CB-1, a first-in-class human monoclonal antibody (human anti-HVEM mAb). We are currently conducting animal studies with promising efficacy results. We have also recently completed the Cell Line Development step for  $\alpha$ 4CB-1, and the CMC process is ongoing. We anticipate beginning our FIH Phase-I clinical trial in approximately 18 months.

In the near future, 4C Biomed will commence its Series A fundraising to support the clinical development of  $\alpha$ 4CB-1.

## **KIOX PHARMA**

**Presenter:** Mikkel Walmar, CEO

Kiox is developing inhaled treatments for rare lung diseases. We focus on diseases with no or limited treatment options. We currently have 3 inhaled treatments in our pipeline. Our most progressed product (KX01) is an inhaled anti-inflammatory treatment for Bronchiolitis obliterans syndrome a severe and often deadly complication after lung transplant and allogeneic stemcell transplantation. Kiox plans to initiate clinical trials in early 2025 and is seeking investors for early phase clinical development. The founding team of Kiox and its advisors have strong experience within both rare lung disease and inhalation product development.

## **minovia**

mitochondrial  
therapies

**Presenter:** Natalie Yivgi Ohana,  
Co-Founder and CEO

Minovia is a clinical stage company focused on the development and application of mitochondrial cell therapies for patients suffering mitochondrial dysfunction. Mitochondrial Augmentation Technology (MAT) is a cell therapy platform where an off-the-shelf allogeneic isolated mitochondria are developed as cryopreserved, healthy and functional, energy producing organelles and used to augment various cell types to be used as therapeutics products. The lead product, MNV-201 consists of autologous hematopoietic stem and progenitor cells (HSPCs) augmented ex vivo with healthy mitochondria. MNV-201 is currently in clinical trials for Pearson

Syndrome and in Pre-clinical stage for Myelodysplastic Syndrome (MDS) indicating encouraging clinical and pre-clinical proof-of-concept for both primary mitochondrial diseases and age-related bone marrow failures. In Minovia we developed novel mitochondria-based biomarkers that allows us to stratify patients according to their "MitoScore". A strong correlation was observed between mitochondrial quality and response to MAT in patients with MDS. Minovia is establishing a novel aspect of cell therapy quality focusing on mitochondrial science, developing robust analytical methods to measure cellular mitochondrial function, as well as modalities to rescue mitochondrial dysfunction in different cell therapies.



**Presenter:** Stefano Gulla, CSO

Kling Biotherapeutics is a clinical-stage, privately held biotech company focused on discovery and

development of antibody based therapeutics. The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.



**LifT BioSciences** Presenter: Alex Blyth, CEO

LifT are world leaders in CAR-Alpha Neutrophil technology and are now preparing to enter clinical trials for high unmet need solid tumours. Our focus is on a unique type of neutrophil known as an Immunomodulatory Alpha Neutrophil (IMAN). We've developed an innovative allogeneic immuno-cell therapy platform that not only directly eliminates cancer cells but also acts as an immunotherapy, recruiting the patient's own immune system to continuously combat the tumor by catalyzing a sustained immune response. IMANs are hundreds of times more potent than a cancer patient's own dysfunctional neutrophils.

Contents 

# Biotech Room 2 Pitches: Morning

**Theme:** Dx and More

**Moderator:** Bauke Anninga, M Ventures

**PRO**  **LT**

**Presenter:** Juan Ignacio Imbaud, CEO

---

PROTEIN ALTERNATIVES

Spanish biotech company based in Madrid developing Therapeutic, Prognostic and Diagnostic products for colorectal cancer.

**ADOR**   
D I A G N O S T I C S

**Presenter:** Eran Zahavy, CEO

ADOR Diagnostics is an innovative diagnostics (IVD) company with its primary R&D and operations based in

Israel, Italy, and Germany. It has made substantial investments in pioneering technology to create a groundbreaking Point-of-Care (POC), sample-to-answer, syndromic multiplex diagnostic system.

This cutting-edge development includes the development of a unique molecular biology Isothermal amplification method known as PA/RCA. Additionally, ADOR has introduced a unique electronic carbon-based multiplex sensor, disposable cartridges, and a versatile benchtop instrument. The company takes pride in extensive patent protection, ensuring the safeguarding of its innovative concepts.



**Presenter:** Torbjørn Furuseth, CEO  
and Co-Founder

DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists' existing workflow.



**Presenter:** David Becedas, CEO

Leveraging AI-predictive analytics to improve patient outcomes and health systems' financial outcomes.



**Presenter:** Francois R. Martelet, CEO

Researching and developing novel medicines targeting cancer drug

resistance is at the core of what we do at Scandion Oncology, in our aim to transform the future of cancer therapeutics.

Our efforts are driven by our dedicated pre-clinical and clinical teams together with collaborators, advisors and key opinion leaders, with the focus of solving the unmet medical need for patients with drug resistant cancers.

Contents



# Tech Room Pitches: Afternoon

**Theme:** Novel tech solutions for the Life Sciences

**Moderator:** Oliver Hardick, M Ventures



**Presenter:** Yaakov Nahmias,  
Founder and CSO

Tissue Dynamics is a disruptive pharmtech company advancing novel therapies by unraveling the dynamics of human disease. Through its cohesive and innovative approach, Tissue Dynamics is not just advancing drug development but is also redefining the paradigms of precision medicine and therapeutic intervention.



**Presenter:** Hugh Simons, CEO

We're democratising life science with an automated, intuitive and affordable microscopy system based on novel imaging technology.



**Presenter:** David Baum, CEO

Genopore was founded in 2022, specializing in nanopore sensing technologies. Genopore is developing a

proprietary and innovative, semiconductor-based protein detector system that uses unique optical nanopore sensor technology. The technology will provide a flexible and powerful tool with broad applications for drug discovery, clinical diagnostics, the food industry, agriculture, and academic basic research



**Presenter:** Kashif Sadiq, Founder and CEO

DenovAI Biotech is a generative AI-based biotech company pioneering a platform to drive the accelerated and scalable development of multiple biologic therapeutic assets, with emphasis on broadening the scope to challenging targets and unmet medical needs. We are pursuing this both through an in-house pipeline as well as through collaborative partnerships and are currently seeking financing for our Series A round.



**CEREBRIU**  
TRANSFORMING RADIOLOGY

**Presenter:** Robert Lauritzen, CEO

Cerebriu is a Danish digital health radiology company automating MRI for brain diagnostic imaging, empowering radiologists with optimized workflows, and bringing clinical intelligence at the point of imaging.

We are creating a future of accessible MRI for all, improving health through precision care.



**Presenter:** Jeroen Verheyen, Co-Founder and CEO

semarion

Semarion is an advanced materials company spun out from the Cavendish Laboratory in Cambridge. We are accelerating in vitro drug discovery by supercharging adherent cell assays to produce better data faster. Our proprietary SemaCyte<sup>®</sup> microcarrier platform leverages novel materials physics to move and barcode adherent cells. We introduce flexibility, miniaturisation, and multiplexing into existing drug discovery workflows to deliver 10x gains in data.

Contents



# Biotech Room 1 Pitches: Afternoon

**Theme:** More in drug development

**Moderator:** Eva Haas, Optimum Strategic Communications



**Presenter:** Carolyn Porter, CEO

Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition to maintain levels of critical proteins that are otherwise destabilised in certain diseases. Blocking E3 Ligase activity enables protein stabilisation “at source” compared to other approaches and is applicable to a range of indications including oncology and neurology. Outrun has applied its proprietary discovery platform to build a pipeline of first-in-class E3 ligase inhibitors to prevent protein degradation. Outrun’s lead program is a small molecule inhibitor targeting an E3 ligase that destabilizes a tumour suppressor protein in hard-to-treat solid tumours. Spun out of Professor Satpal Virdee’s lab at Dundee University, Outrun is lead by a seasoned management team and Board and backed by M Ventures and MP Healthcare Venture management.



**Presenter:** Anja Harmeier

Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating demyelinating diseases such as multiple sclerosis, optic neuritis or nerve injuries. Our experienced team of CNS drug developers have built a strong patent estate for the development of novel remyelination therapies. Rewind Therapeutics is based in Leuven, Belgium, and backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Sunstone, CD3/ KU Leuven, and Gemma Frisius Fonds.



**Presenter:** Willem van Weperen, CEO

Pluvia Biotech, a spin-out from the University of Bergen, Norway, is having significant momentum with its oral pharmacological chaperones for the rare disease, PKU. Our lead product PBAS499 shows strong pre-clinical Proof of Concept data in PKU models and a clean safety profile. We are targeting a €15M Series A round to take the project next year into Phase 1/2 to demonstrate clinical Proof of Concept in PKU patients.



**Presenter:** Mike Davies, CEO

**Carocell Bio** are developing novel anti-inflammatory peptides to more safely treat serious inflammatory diseases. Our lead, JEL3108, is to safely treat atopic dermatitis (AD, eczema). Our data says we could topically treat the flare, repeat treatment to prevent the disease coming back. Repeat, daily application should delay ageing of the skin.



**Brigid bio**  
Antifungals by Design

**Presenter:** Dr Soumya Palliyil,  
CEO and Co-Founder

BrlgID Bio is a biotech spin-out from the University of Aberdeen, developing novel, first in class antibody-based drugs as safer and efficacious treatment solutions for high-risk and drug resistant fungal infections. BrlgID Bio utilises a unique and proprietary platform where the identification of pathogen specific cell wall markers provides an opportunity to develop targeted therapies. Combining the scientific expertise of two world leading centres of excellence - Aberdeen Fungal Group and Scottish Biologics Facility, we have developed fully human antibodies (mAbs) that target key cell wall markers which are unique to fungal pathogens and critical for infection and resistance. The cell wall targets we have identified are completely novel and have never been used in drug discovery, offering a strong IP protection. Our lead, fully human antibodies have demonstrated superior therapeutic efficacy in a 'clinically predictive' mouse model of invasive candidiasis.



**Presenter:** Toby Wilson Waterworth,  
CEO

Ambrose Healthcare is an award-winning pharmaceutical start-up focused on rare diseases. We are addressing the global rare disease challenge with a practical approach. Our experienced team, incorporating human expertise and digital technologies, focuses on building a broad, late-stage portfolio with lower risks. Emphasizing Phase 2b and beyond, where success rates range from 50-90%, we aim to accelerate drug development and reduce costs significantly. Our commitment to entrepreneurship without borders, patient engagement, and a capital-efficient model sets Ambrose apart, reshaping the landscape of rare disease pharmaceuticals.

Ambrose Healthcare strives to deliver impactful solutions, efficiently and effectively, for a world in need.

Contents 

# Biotech Room 2 Pitches: Afternoon

**Theme:** New modalities and administration methods

**Moderator:** Nadiya Ishnazarova, M Ventures



**CREASALLIS**  
The Creative Antibody Solutions Company

**Presenter:** Zahra Jawad, CEO and Founder

Creasallis is a pre-seed antibody therapeutics company who has a technology to improve the penetration of antibodies into solid tumours. The technology is a modification of the constant region of an antibody called CreaTap. The company was founded in 2021 by Zahra Jawad who comes with 17 years experience in developing antibody based drugs for clinical use. Creasallis raised a VC lead pre-seed round in December 2022.

**ALDER**  
**THERAPEUTICS**

**Presenter:** Stijn Heessen, COO

Alder Therapeutics is a Swedish private pre-clinical stage stem cell therapy development company with two promising allogeneic programs in the pipeline with preclinical proof of concept data. Our first and most advanced program ALD01 is a retinal cell therapy to treat Retinitis Pigmentosa (RP). ALD01 could revolutionize RP treatment, offering a mutation agnostic option for most patients.

Our second program ALD02 is a cardiac cell therapy for patients suffering from heart failure. ALD02 is aimed at regenerating damaged heart tissue in those patients through non-invasive administration of stem cell-derived heart muscle cells.

The seasoned and agile Alder team works with global cell therapy experts all focused on bringing Alder's unique therapy options to patients. Backed by Swedish investors Flerie and Linc, we are now looking for an active lead investor to take our lead program to the clinical stage.



**Presenter:** Carlota Dopico, Business Development and Innovation

Mikrobiomik is a biopharmaceutical company born for the research, development, production and commercialization of biologic medicines based on the human microbiome. At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently with no therapeutic alternative. Our first investigational biological drug, MBK-01, aimed at the treatment of intestinal infection by *Clostridioides difficile*, has announced the closure of the phase III clinical trial, and patient recruitment has been completed in November 2023. The regulatory dossier will be presented to the EMA (European Medicines Agency) in 2024, via a centralized channel and its commercialization is expected during the first half of 2025.



**Presenter:** Lars Nieba, CEO

Engimmune Therapeutics is a world-class developer of targeted, highly potent ‘off-the-shelf’ soluble T-cell receptor drugs (TCRs) to treat solid tumour cancers. Our cutting-edge proprietary platform technologies enable us to rapidly identify and engineer multi-specific soluble TCRs for extremely high target affinity, enhanced stability, and superior safety to trigger potent and durable immune cell responses against solid tumours.

Our AI-guided protein engineering platforms are designed to overcome important challenges associated with soluble TCR development, unlocking thousands of new targets to develop transformative treatments for solid cancers and immune-mediated diseases.



**Presenter:** Carrie Ambler, CSO

LightOx has developed a new chemotherapy treatment for early-stage oral cancer patients. Our drug, LXD191, is a new chemical entity that can be applied topically to the area of interest and activated using a specific wavelength of light. Our second programme in the pipeline uses the light activated technology to target infection in wounds. Using a gel product, the agent actively targets bacterial species in surgical, chronic or post operative wounds.

# **metaLead** **Presenter:** Michal Shoshan, CEO and Founder

metaLead Therapeutics ApS is a preclinical stage start-up developing best-in-class drugs to treat metal-related diseases. Our core technology is based on novel short peptides that serve as selective, benign, and orally available chelating agents. We are currently targeting Wilson's disease as our first indication.

Contents



# Exhibitors



As a trusted partner for biopharmaceutical and medical device companies, we have one-stop-shop clinical research capabilities in high recruiting countries. We deliver regulatory, pharmacovigilance and medical information excellence as a CRO in Europe, CIS, EAEU, MENA, LATAM regions and the US throughout the entire product lifecycle. We ensure clients satisfaction by rapid, efficient and cost-effective working practices.



A co-organiser of the Anglonordic Life Science Conference, BioPartner UK is the independent, accredited trade organisation that supports UK international trade.

We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to entry fee discounts for key Life Science conferences.



Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative

biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface.



As data-driven and quality-focused clinical CRO, OPIS collaborates with numerous international Sponsors on multi-country interventional as well as

non-interventional trials. OPIS teams have sound experience in a wide range of therapeutic areas, new-generation drugs, advanced therapeutic procedures and biologic treatment options.



A co-organiser of the Anglonordic Life Science Conference, we are dedicated to delivering strategic communications

and investor relations programmes for healthcare, life sciences or industrial-biotech businesses.



Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development with our expertise in

biologically relevant assay systems. We offer a range of customized services, from confirming target engagement to strengthening target validation and understanding the mechanism of action of your compounds. Our approach is designed to help you make better decisions faster, no matter where you are in the drug discovery process.



**The Anglonordic Charity of the Year.**

See the [COTY feature page](#) below, which includes details on how to donate.

**scantox** Silver Sponsor

Scantox is the leading Nordic preclinical GLP accredited CRO.

Our main focus is on pharmacology and regulatory toxicology and based on decades of experience, we are a trusted partner for product development services within the pharmaceutical and medical device industries.

# SCENDEA

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs.



# Delegations

Leading organisations within some of the countries represented at the Anglonordic Life Science Conference are supporting delegations of attending companies from within their region.



**The Danish Trade Council and Invest in Denmark** based at the Royal Danish Embassy in London are proud to be representing a delegation of companies from the Danish Life Science Cluster. Denmark is home to one of the strongest life science clusters in the world with some of the largest global companies and innovative start-ups, all looking for global cooperation.



**NELEP (North East Local Enterprise Partnership)** supports regional growth in North East England, which encompasses a population of two million people and a skilled and resilient workforce, producing goods and services valued at around £41 billion annually.



**Spanish Bioindustry Association (AseBio)** brings together and represents the interests of companies, associations, foundations, universities and technology and research centres that work in the field of biotechnology in Spain.

Contents 

# Charity of the Year



The Anglonordic Charity of the Year is [Roald Dahl's Marvellous Children's Charity](#).

The Charity provides specialist nurses and support for seriously ill children. There are currently over 120 Roald Dahl Nurses caring for more than 33,000 seriously ill children, but there are still too many children with serious illnesses who do not receive this vital specialist care.

Roald Dahl Nurses are trained and dedicated experts in their field. They are a consistent presence in the child's life from initial diagnosis through to the child's transition to adult services. They advise, they reassure, and they become an extended part of the family.

[Donate!](#)

**Fund a Roald Dahl Nurse today**

[roalddahlcharity.org/donate](https://roalddahlcharity.org/donate)




# ATTENDING INVESTORS

3xP Global	BioGeneration	First Spark Ventures
4BIO Capital	Ventures	Forbion
Abbvie Ventures	BPC	Future Planet Capital
Abingworth	Brandon Capital	General Inception
Advent Life Sciences	British Patient Capital	GGG Associates
Aglaia Oncology Funds	Calculus Capital	Global Brain
AlbionVC	Cancer Research Horizons	Guerbet
Amadeus Capital Partners	Catalio Capital	H Tree Capital
Angel Investor	Cathay Capital	HCVC
ARCH Venture Partners	Cell and Gene Therapy Catapult	Hermes Partners Intl.
Arix Bioscience	CEPI	Hummingbird Ventures
Astellas	CGT Catapult	i2020 Accelerator
Axilium Holding	CPI Enterprises	Ignite Capital Partners
Baltic Sandbox Ventures	Deep Science Ventures	Illumina Ventures
BATM Advanced Communications	Delin Ventures	Illumina Ventures Labs
BGF	Empirical Ventures	Innovestor Life Science Oy
	Epidarex	Intermediate Capital Group
	Evotec Ventures	

IP Group plc	Oppenheimer & Co.	UCB Ventures
JJDC	Inc.	UCL Technology
Johnson and Johnson	OrbiMed	Fund
Innovation	OSE	UKI2S
LifeArc Ventures	Oxford University	Venturebeam
Lilly Ventures	Innovation	Vesalius Biocapital
M Ventures	Panakes Partners	Partners
Macmillan Cancer	Parkwalk Advisors	Wilbe Group
Support	Redalpine Ventures	
Meltwind	RM Global	
Mercia Ventures	Rosetta Capital	
Molten Venture	RYSE Asset	
Monograph	Management	
MVM Partners	Shionogi	
New Science Fund	Simris Group	
NG Bio	Sofinnova Partners	
Norgine Ventures	SOSV	
Novo Holdings	Start Codon	
Novo Nordisk	Syncona	
o2h Group	The Pioneer Group	
Octopus Ventures	Triton Partners	
OMX Ventures	TusPark Holdings	

Contents



# ATTENDING COMPANIES AND ORGANISATIONS

3xP Global	Ambrose Healthcare	Baltic Sandbox Ventures
4BIO Capital	Angel Investor	BATM Advanced Communications
4C Biomed	ANYO Labs	BGF
Abbvie Ventures	ARCH Venture Partners	BIA
Abingworth	Argentum Consultants	BioCentury
ADOR DX	Arix	BioGeneration Ventures
Advent Life Sciences	Aryium	BioLizard
Aglaia Oncology Funds	Asahi Kasei Pharma Corporation	Biomapas
AlbionVC	Asceneuron	BioMixing
Alchemab Therapeutics	ASEBIO	Bionow
Alcyomics	Astellas	BioPartner UK
Alder Therapeutics	Astraveus	Biopharma Illuminata
AlgoDx	AstraZeneca	BioSell
Altasciences	AWEX - Belgian trade office for Wallonia	Biotechnology Business Institute (BBI)
Amadeus Capital Partners	Axilium Holding	BPC
Amalus Therapeutics		

Continued on p50



# UPCOMING EVENTS

Get exclusive discounts for the world's premier  
Life Sciences Events

	<p><b>BIO INTERNATIONAL CONVENTION 2024</b> <b>SAVE UP TO 15.5% (\$550).</b> The standard rate is \$3550. The price you pay will be \$200-\$550 less depending on your membership affiliation.</p>	<p>June <b>3-6</b> SAN DIEGO, USA</p>
	<p><b>BIO-EUROPE 2024</b> <b>SAVE UP TO 30% with BioPartner UK, and optionally join the UK Delegation.</b> The standard rate is €4743.75 (includes 25% VAT). Save up to 50% (includes early members rate, and VAT savings)</p>	<p>Nov <b>4-6</b> STOCKHOLM, SWEDEN</p>

Visit our [Members Page](#) to check your discount eligibility.

Brandon Capital	Citeline	DoMore
Breakpoint Therapeutics	Clair Scientific	Diagnostics
Brigid Bio	Clarivate	DragonLight Films
British Patient Capital	CNX Therapeutics	Drug Discovery World
Business Region Göteborg	Collaborative Drug Discovery	DTRE
Business Sweden	Comac Medical	Empirical Ventures
Calculus Capital	Concept Life Sciences	Endpoints News
Cancer Research Horizons	Consensus Business Group	Engimmune Therapeutics AG
Carbogen-Amcis	Cooley	Epidarex
Carocell Bio	Covington & Burling	Evotec Ventures
Catalent	CPI Enterprises	Ezenze
Catalio Capital	Creasallis	First Spark Ventures
Cathay Capital	Curve Therapeutics	Five Alarm Bio
CatSci	Danish Embassy London	Forbion
Cell and Gene Therapy Catapult	Deep Science Ventures	Forresters
CELLOMATICS BIOSCIENCES	Delin Ventures	FoRx Therapeutics
Celtarys Research	DenovAI Biotech	FreeMind Group
CEPI	DNA Electronics	Future Planet Capital
Cerebriu		General Inception
		Genopore
		GGs Associates

Global Brain	Innovestor Life	LBIC (London
GlobalData	Science Oy	BioScience
Grand River	Intermediate	Innovation Centre)
Aseptic	Capital Group	LifeArc Ventures
Manufacturing	Invest in Denmark	LifT BioSciences
Guerbet	IP Group plc	LightOx
H Tree Capital	IQVIA	Lilly Ventures
Harmonic	Isogenica	LINK Medical
Discovery	Jetbio	Research
HCVC	JJDC	Lisa Urquhart
Health Tech Hub	Johnson and	Liva Healthcare
Copenhagen	Johnson Innovation	Lonza
Hermes Partners	Kaneka-	M Ventures
Intl.	Eurogentec	Macmillan Cancer
Hummingbird	King's College	Support
Ventures	London	Magnitude
i2020 Accelerator	KINSY	Biosciences
Ignite Capital	Kiox Pharma	Medical Device
Partners	klas therapeutics	Network
Iktos	Kling	Medicon Valley
Illumina Ventures	Biotherapeutics	Alliance
Imperial College	Kvantify	Medilink North of
London	Lant Medical	England
IMU Biosciences		MEDiSTRAVA
In Vivo - Citeline		MediWales

Meltwind	Novo Holdings	Partisia
Mercia Ventures	NunaBio	Pelago Bioscience
Merck KGaA	Nxera Pharma	Pharma Holdings
Mergermarket	o2h Group	Pharmacelera
metaLead Therapeutics	Octopus Ventures	Pluvia Biotech
MetalloBio	OMX Ventures	Predicare
MicroA	One Nucleus	Probatech
Microverse Studios	OnePass Medical	Prokarium
Mikrobiomik Healthcare	Onyx Scientific	Protagoras Group
Minovia Therapeutics	OPIS	PROTEIN ALTERNATIVES
Mission Therapeutics	Oppenheimer & Co. Inc.	PulmoBioMed
Molten Venture	Oppilotech	Quadram Institute Bioscience
Monograph	Optimum Strategic Communications	QuantHealth
MSD	OrbiMed	Reading Scientific Services (RSSL)
MVM Partners	OSE	Redalpine Ventures
NanoSyrinx	Otsuka Pharmaceuticals	Rewind Therapeutics
Nature and Evaluate	Outrun Therapeutics	RM Global
New Science Fund	Oxford University Innovation	Roald Dahl's Marvellous Children's Charity
NG Bio	Panakes Partners	Rosetta Capital
Norgine Ventures	Parkwalk Advisors	

Russell Publishing	STORM	Wiborg
RxSource Clinical Services	Therapeutics Syncona	International Holding
RYSE Asset Management	Syneos Health	Wilbe Group
Scandion Oncology	Tasen Consulting	WuXi Biologics
Scantox Group	The Francis Crick Institute	WuXi STA
Scendea	The Pharma Letter	
Science Ventures Denmark	The Pioneer Group	
SciTribe	Tissue Dynamics	
SEHTA	Triton Partners	
Semarion	TusPark Holdings UK	
Shionogi	UCB Ventures	
Simris Group	UCL Technology Fund	
SmartMoneyMatch	UKI2S	
Sofinnova Partners	University of Southern Denmark	
Sosei Heptares	Venturebeam	
SOSV	Veranova	
Space M	Vesalius Biocapital Partners	
SpliceBio	Vesper Bio	
Start Codon		
Sterling Pharma Solutions		

